RxDoctor Payments Data

Shawna Schmidt, MD

Pain Medicine · Aberdeen, SDNPI 1770603888

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,150 of the $5,327 with a category attached, or 77.9%. Medtronic accounts for 96.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $3,137 and has fallen 98.3% since, to $53 in 2025.

$5,327in general payments, 2019–2025

Across 51 payments — averaging $104.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • AbbVie$115
  • Amgen$28
  • Vertex$21
  • Lundbeck LLC$15
  • Nevro Corp.$13
  • plus $23 from 2 others

What the payments were for

  • Travel & lodging$4,15078%
  • Food & beverage$1,17822%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic39$5,112
AbbVie6$115
Amgen1$28
Vertex1$21
Lundbeck LLC1$15
Nevro Corp.1$13
Pfizer1$12
Supernus Pharmaceuticals, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$134,227
Medicare patients
472
Services billed
2,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant21$21,633
NucyntaTapentadol Hcl22$20,384
OxycontinOxycodone Hcl32$17,416
Aimovig AutoinjectorErenumab-Aooe13$9,905
ButransBuprenorphine16$8,637
LyricaPregabalin13$8,083
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen363$7,043
Fentanyl51$6,761
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen150$3,086
Gabapentin320$3,034
Buprenorphine11$2,529
Pregabalin156$2,210
Morphine Sulfate ErMorphine Sulfate66$1,908
Baclofen126$1,900
Tizanidine Hcl91$1,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$115$21,63321 claims
PfizerLyrica$12$8,08313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain medicine providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other pain medicine in Aberdeen

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →